Keywords: Teva, 4th quarter and full year 2009 financial results, Barr
Teva returns to profit, as 4th quarter 2009 sales leap 33%
Article | 16 February 2010
Israel-based generics drug giant Teva Pharmaceutical Industries met analysts’ forecasts, reporting fourth-quarter 2009 net profit of $379 million, or $0.42 per share, compared ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
